Amgen
- AMGN
- NASDAQ
- Consumer Products
- Latest 105.57
- Currency US$
- Change 1.04
- Percent Change 0.995 %
- Volume 2,236,894
- Thu May 23, 2013 3:25 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 103.10
- Previous Close 104.53
- High 106.33
- Low 103.00
- Bidx3 105.55
- Askx3 105.58
- 52-week High 04/23 114.95
- 52-week Low 06/01 67.61
- Beta 0.404
- Market Cap 79,011.76M
- EPS 6.83
- P/E 15.50
- Forward P/E 12.704
- PEG 1.66
- Annual Dividend 1.88
- Yield 1.781
News
- Amgen Announces Voting Results of Annual Meeting of Stockholders
- Amgen To Present At The UBS Global Life Sciences Conference
- New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer
- Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
- Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Financials & Calendars
- Sales $17,455,000,000
- Earnings $4,595,000,000
- Return on Equity 23.84%
- Cash Flow --
- Cash $2,530,000,000
- Current Ratio 5.58
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $51,640,000,000
- Liabilities $32,149,000,000
- Liabilities-to-Equity Ratio 1.65
Price Ratios
- Price to Sales 4.53
- Price to Book 4.05
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Apr 23 | $1.75 | Jul 25 | $1.68 |
| Surprises | Apr 23 | 11.43% | n/a | n/a |
| Dividends | May 14 | $0.47 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 23, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
Officers
- Robert A. Bradway Chairman of the Board; Preside
- Jonathan M. Peacock Executive Vice President and C
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
ONE AMGEN CENTER DRIVETHOUSAND OAKS, CA
91320
Phone: (805)-447-1000
Fax: (805)-4471010
Ideas & Discussion
Live Discussion of AMGN on StockTwits